ARCHIVES

Cancer Groups Endorse Richard Pazdur for Head of FDA’s New Office of Oncology Drug Products. Five Candidates Are In the Running for the Job, Sources Said.

This article is from The Cancer Letter archive.

Vol. 31 No. 07 | February 18, 2005

Download PDF Visit The Full Archive

Related Articles

Amgen Cancels Rilotumumab Trials in Gastric Cancer

December 26, 2014

ODAC Rejects Amsacrine NDA, Renews Idarubicin

September 14, 1990

NCI Plans Brain Tumor Study To Determine Risk Factors, Exposures

April 16, 1993

AACR Receives Record Number of Abstracts

January 27, 1989

In Brief: Deisseroth Leaves M.D. Anderson To Head Yale’s Oncology, Gene Therapy Programs

September 15, 1995

Review Of Cancer Center supports Grants Needs Refocus On Science, Advisors Say

October 18, 1996